4,5-Dichloro-2-[[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]pyridazin-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4,5-Dichloro-2-[[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]pyridazin-3-one
• 化学式: C₁₃H₇Cl₃N₄O₂
• 分子量: 357.6
• InChiKey: JZLIRWOEBPNNEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Parkin ligase activation methods and compositions
  申请人：An2H Discovery Limited

  公开号：US10155936B2

  公开（公告）日：2018-12-18

  The present invention is directed to methods and compositions for activating a Parkin ligase by administering to a subject in need thereof a therapeutically effective amount of a compound that disrupts at least one Parkin ligase zinc finger. The present invention is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase.

  本发明涉及通过向有需要的受试者施用治疗有效量的破坏至少一个Parkin连接酶锌指的化合物来激活Parkin连接酶的方法和组合物。本发明还涉及治疗和/或降低与激活Parkin连接酶有关的疾病或病症发病率的方法。
• Pyridazinones and their use in the treatment of cancer
  申请人：Arnér Elias Set Jenö

  公开号：US11110089B2

  公开（公告）日：2021-09-07

  There is provided compounds of formula (I) or pharmaceutically-acceptable salts thereof, wherein W, X, Y, Z, R1, R2 and R3 have meanings provided in the description, which compounds are useful in the treatment of cancers.

  提供了式 (I) 的化合物或其药学上可接受的盐类，其中 W、X、Y、Z、R1、R2 和 R3 的含义见说明，这些化合物可用于治疗癌症。
• PYRIDAZINONES AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Arnér, Elias, Set Jenö

  公开号：EP3331878A1

  公开（公告）日：2018-06-13
• PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS
  申请人：An2H Discovery Limited

  公开号：US20160160205A1

  公开（公告）日：2016-06-09

  The present invention is directed to methods and compositions for activating a Parkin ligase by administering to a subject in need thereof a therapeutically effective amount of a compound that disrupts at least one Parkin ligase zinc finger. The present invention is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase.
• THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER
  申请人：Cinda Pharma AB

  公开号：US20210038577A1

  公开（公告）日：2021-02-11

  The present invention provides inhibitors of thioredoxin reductase, in particular selenium compromised thioredoxin reductase-derived apoptotic protein (SecTRAP) forming agents, for use in treating an immune cell infiltrated cancer (e.g. a T-cell infiltrated cancer) in a subject, wherein said agents stimulate an anti-cancer immune response. The present invention also provides combinations comprising a SecTRAP forming agent and other therapeutic agents for use in treating cancer.